PMID- 14754959
OWN - NLM
STAT- MEDLINE
DCOM- 20040303
LR  - 20190605
IS  - 1098-4275 (Electronic)
IS  - 0031-4005 (Linking)
VI  - 113
IP  - 2
DP  - 2004 Feb
TI  - Management of a severe carbamazepine overdose using albumin-enhanced continuous 
      venovenous hemodialysis.
PG  - 406-9
AB  - Carbamazepine intoxication is common in the pediatric population. Highly 
      protein-bound, carbamazepine is not removed efficiently through conventional 
      hemodialysis. We describe the use of albumin-enhanced continuous venovenous 
      hemodialysis (CVVHD) in a 10-year-old girl who developed coma and respiratory 
      depression due to an intentional carbamazepine overdose (peak drug level of 44.8 
      microg/ml; therapeutic range: 8-12 microg/ml). Without intervention, the 
      half-life of drug elimination is 25 to 60 hours in patients who are naive to 
      carbamazepine and 12 to 20 hours in children on chronic carbamazepine therapy. In 
      contrast, with albumin-enhanced CVVHD, we observed a half-life of 7 to 8 hours. 
      The patient recovered rapidly and was discharged from hospital <4 days from the 
      time of ingestion with no complications or neurologic impairment. Because the 
      cost-benefit analysis was also favorable relative to other therapeutic options, 
      albumin-enhanced CVVHD may be the optimal treatment of toxic-level ingestion of 
      carbamazepine.
FAU - Askenazi, David J
AU  - Askenazi DJ
AD  - Renal Section, Department of Pediatrics, Baylor College of Medicine, Houston, 
      Texas 77030, USA.
FAU - Goldstein, Stuart L
AU  - Goldstein SL
FAU - Chang, I-Fen
AU  - Chang IF
FAU - Elenberg, Ewa
AU  - Elenberg E
FAU - Feig, Daniel I
AU  - Feig DI
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
RN  - 0 (Anticonvulsants)
RN  - 33CM23913M (Carbamazepine)
SB  - IM
MH  - Anticonvulsants/blood/*poisoning
MH  - Carbamazepine/blood/*poisoning
MH  - Child
MH  - Drug Overdose/therapy
MH  - Female
MH  - *Hemofiltration
MH  - Humans
EDAT- 2004/02/03 05:00
MHDA- 2004/03/05 05:00
CRDT- 2004/02/03 05:00
PHST- 2004/02/03 05:00 [pubmed]
PHST- 2004/03/05 05:00 [medline]
PHST- 2004/02/03 05:00 [entrez]
AID - 10.1542/peds.113.2.406 [doi]
PST - ppublish
SO  - Pediatrics. 2004 Feb;113(2):406-9. doi: 10.1542/peds.113.2.406.